Examkin

Question

Difficulty: MediumMonitoring and Treatment Evaluation

A 54-year-old man visits the outpatient clinic for a scheduled assessment. He underwent a mechanical aortic valve replacement three years ago. His daily medications include warfarin and low-dose aspirin. Over the past month, the patient has felt a persistent low mood and decided to start taking an over-the-counter herbal supplement, St. John's wort. He reports no episodes of bleeding, bruising, chest discomfort, or dyspnea. Vital signs are within normal limits. Cardiovascular examination demonstrates a crisp prosthetic valve click with no murmurs. Today, his International Normalized Ratio (INR) is 1.4; his previous value four weeks ago was 2.6. Which of the following is the most appropriate next step in the management of this patient?

  1. Counsel the patient to discontinue the herbal supplement and repeat the INR in one weekAnswer
  2. B
    Maintain the current medication regimen and schedule a repeat INR in four weeks
  3. C
    Discontinue warfarin therapy and transition to oral rivaroxaban
  4. D
    Administer low-dose oral phytonadione
  5. E
    Order a transesophageal echocardiogram to evaluate for valve thrombosis

Answer

Counsel the patient to discontinue the herbal supplement and repeat the INR in one week
The correct action is to advise the patient to stop taking St. John's wort and to recheck the INR in one week. Patients with a mechanical aortic valve require lifelong anticoagulation with a target INR of 2.0 to 3.0. St. John's wort is a well-known inducer of several cytochrome P450 enzymes, notably CYP2C9 and CYP3A4. Because warfarin is primarily metabolized by CYP2C9, induction of this enzyme increases warfarin clearance, significantly reducing its serum concentration and clinical effect. This manifests as a subtherapeutic INR, placing the patient at increased risk for valve thrombosis and systemic embolization. The most appropriate and direct intervention is to remove the interacting agent. Since the synthesis and half-lives of vitamin K-dependent clotting factors take several days to equilibrate, repeating the INR in approximately one week is the standard protocol to verify that the INR is rising back into the therapeutic range.

Step-by-Step Solution

1
Analyze the patient's presentation and laboratory findings.
The patient has a mechanical aortic valve (target INR 2.0-3.0) and presents with a subtherapeutic INR of 1.4.
Identifying the deviation from the therapeutic target is the first step in recognizing the clinical problem.
2
Identify the cause of the subtherapeutic INR.
The patient recently started St. John's wort, which is a known potent inducer of hepatic cytochrome P450 enzymes.
Determining the etiology of the lab abnormality directs the management approach.
3
Determine the most appropriate management.
Discontinue the offending agent (St. John's wort) and recheck the INR in approximately one week to ensure it returns to the therapeutic range.
Removing the interacting drug will reverse the enhanced metabolism of warfarin without unnecessarily exposing the patient to other invasive interventions or contraindicated medications.

Key Concept

St. John's wort is a potent inducer of cytochrome P450 enzymes (including CYP2C9 and CYP3A4), which accelerates the metabolism of warfarin, leading to a subtherapeutic International Normalized Ratio (INR).
Rate this question

Topics

Monitoring and Treatment Evaluation

More questions from this topic